Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

@article{Hanna2004RandomizedPI,
  title={Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.},
  author={Nasser H Hanna and Frances A. Shepherd and Frank V. Fossella and Jos{\'e} Rodrigues Pereira and Filippo de Marinis and Joachim von Pawel and Ulrich Gatzemeier and Thomas Chang-yao Tsao and M. Pless and T Muller and Hong Liang Lim and Christopher E. Desch and Kl{\'a}ra Szondy and Radj Gervais and Shaharyar and Christian Manegold and Sofia Paul and Paolo Paoletti and Lawrence H. Einhorn and Paul A Bunn},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 9},
  pages={
          1589-97
        }
}
  • N. Hanna, F. Shepherd, P. Bunn
  • Published 1 May 2004
  • Medicine, Biology
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. PATIENTS AND METHODS Eligible patients had a performance status 0 to 2, previous treatment with one prior chemotherapy regimen for advanced NSCLC, and adequate organ function. Patients received pemetrexed 500 mg/m(2) intravenously (i.v.) day 1 with vitamin B(12), folic acid, and dexamethasone or docetaxel 75 mg/m(2) i.v… 

Phase II Study of Pemetrexed and Cisplatin, with Chest Radiotherapy Followed by Docetaxel in Patients with Stage III Non-small Cell Lung Cancer

  • S. GadgeelJ. Ruckdeschel A. Turrisi
  • Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2011
TLDR
Integrating pemetrexed in a concurrent therapy regimen for patients with stage III NSCLC is feasible and was associated with a median survival of 34 months and overall survival of 66%.

Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer

TLDR
This cisplatin-free regimen with gemcitabine plus pemetrexed had good tolerance and achieved promising overall survival with extended 1- and 2-year survival rates.

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer

  • Young Saing KimE. Cho D. Shin
  • Medicine, Biology
    Cancer research and treatment : official journal of Korean Cancer Association
  • 2016
TLDR
Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treatment in unselected patients with advanced NSCLC, however, pemberrexed is considered more effective than gef itinib for EGFR wild-type patients.

Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.

  • E. SmitS. Burgers H. Groen
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
PC as second-line treatment for relapsed NSCLC resulted in a significant 33% reduction of the hazard of disease progression as compared with pemetrexed alone, and adenocarcinoma was associated with favorable outcome.

Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer

  • D. SpigelJ. Hainsworth F. Greco
  • Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2010
TLDR
Biweekly administration of pemetrexed and gemcitabine seems to be well tolerated with activity comparable with other first-line NSCLC regimens, and whether biweekly scheduling could be an effective strategy to shorten overall treatment duration will require a randomized design.

A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-small Cell Lung Cancer

  • R. HeistP. Fidias T. Lynch
  • Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2008
TLDR
Treatment with oxaliplatin and pemetrexed in combination with the targeted antiangiogenic agent bevacizumab yielded promising efficacy with manageable toxicity in the previously treated advanced NSCLC population.

A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer.

TLDR
Oral topotecan appears to be active and well tolerated when administered as a fixed dose daily for 5 of every 7 days for 2 weeks every 21 days and might provide another treatment alternative for patients with advanced-stage NSCLC.
...

References

SHOWING 1-10 OF 17 REFERENCES

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

TLDR
Patients who received docetaxel had a longer time to progression and a greater progression-free survival at 26 weeks and the 1-year survival was significantly greater with D75 than with the control treat...

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

TLDR
Treatment with docetaxel is associated with significant prolongation of survival, and at a dose of 75 mg/m(2), the benefits of docetAXel therapy outweigh the risks.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

TLDR
Treatment with pemetrexed plus cisplatin and vitamin supplementation resulted in superior survival time, time to progression, and response rates compared with treatment with cis Platin alone in patients with malignant pleural mesothelioma.

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.

TLDR
MTA seems to have clinically meaningful activity as a single agent against advanced NSCLC, and nonhematologic toxicity was generally mild or moderate, but 39% of patients developed a grade 3 skin rash.

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

  • R. GrilliA. OxmanJ. Julian
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1993
TLDR
Chemotherapy is effective in the treatment of advanced NSCLC, but its impact on the length of survival is limited, and future RCTs should still include an untreated control group and should measure quality of life in addition to survival.

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

TLDR
The results of this meta-analysis suggest that chemotherapy may have a role in treating non-small cell lung cancer, and reached conventional levels of significance when used with radical radiotherapy and with supportive care.

Current Data with Pemetrexed in Non-Small-Cell Lung Cancer

TLDR
Pemetrexed (Alimta®) is a novel multitargeted antifolate that inhibits 3 enzymes involved in folate metabolism and purine and pyrimidine synthesis that has broad antitumor activity in phase II trials in a wide variety of solid tumors.

Current data with pemetrexed (Alimta) in non-small-cell lung cancer.

  • A. Adjei
  • Biology, Chemistry
    Clinical lung cancer
  • 2003
TLDR
Pemetrexed (Alimta) is a novel multitargeted antifolate that inhibits 3 enzymes involved in folate metabolism and purine and pyrimidine synthesis that has broad antitumor activity in phase II trials in a wide variety of solid tumors.

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

TLDR
The Southwest Oncology Group has extended the toxicity criteria, incorporating additional new criteria for biological agents, radiation therapy, surgery, and hormonal agents.

Design and analysis of non-inferiority mortality trials in oncology.

TLDR
Non‐inferiority analyses that do not involve a fixed margin are proposed that are conditionally equivalent to two confidence interval procedures that relax the conservatism of two 95 per cent confidence interval testing procedures and preserve the type I error rate at a one‐sided 0.025 level.